Duopharma Biotech Berhad (7148.KL)

1.2600 +0.0800 (+6.78%) At close: 04:53PM MYT

Duopharma Biotech Berhad

CIMB HUB
Suite 18.06, Level 18 No. 26, Jalan Sultan Ismail Taman Klang Jaya
Kuala Lumpur 50250
Malaysia
60 3 2162 0218
https://duopharmabiotech.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ariff bin Abdul Shatar	Group MD & Executive Director	2.22M	N/A	1965
Mr. Wu Kong Chek	Chief Financial Officer	N/A	N/A	1966
Mr. Ibrahim Hussin Salleh	Chief Legal Officer & Group Company Secretary	N/A	N/A	1968
Sabrina Binti Haron	Chief Compliance Officer	N/A	N/A	N/A
Mr. Krisnakumara Reddi	Chief Manufacturing & Sustainability Officer	N/A	N/A	1970
Wan Ahmad Nizam Bin Wan Mohd. Salleh	Group Head of Risk Management & Integrity	N/A	N/A	1974
Dr. Anas Bin Alam Faizli	Chief Executive Officer of Corporate	N/A	N/A	N/A
Mr. Shamsul Idham Bin A. Iahad	Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd.	N/A	N/A	1973

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in MYR.

Description

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products comprising vitamins and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, such as diabetes, cancer, cardiovascular diseases, renal diseases, and others. The company's product portfolio comprises vascor, acetan, covasc, crystorvas, bezartan, vytan, and vytocor; insugen and basalog one; kytron, zuhera, lebreta, trevive, and krabeva; and unihepa, ranofer, erysaa, bi-haemosol, and haemosol. The company offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, and Uphamol brands. In addition, it offers property management and services; and distributes, imports, and exports chemical products. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. Duopharma Biotech Berhad was founded in 1978 and is headquartered in Kuala Lumpur, Malaysia.

Corporate governance

Duopharma Biotech Berhad’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.